Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Importance of Testing for CKD Among Patients With Type 2 Diabetes
Author(s): Pam Taub , Nikolaus Marx Added: 1 year ago
RP-UN-CAR-GB-0166 / June 2024This programme features a compelling discussion between two distinguished experts, Prof Pam Taub (University of California, San Diego, US) and Prof Nikolaus Marx (University Hospital RWTH, Aachen, DE), chairperson responsible for the most recent ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes. Together, they delve into a critical… View more

Guidelines & Statements

Prevention & Chronic Conditions
ACC 26: SURPASS-CVOT - Tirzepatide vs Dulaglutide in T2D
Author(s): Steven E Nissen Added: 2 months ago
American College of Cardiology Congress 2026 – Dr Steven Nissen (Cleveland Clinic, Cleveland, OH, US) joins us to discuss the effects of tirzepatide compared with dulaglutide on expanded cardiorenal outcomes from the SURPASS-CVOT trial (NCT04255433; Eli Lilly and Company).This international, double-blind, randomised, phase III cardiovascular outcomes trial enrolled 13,299 patients aged 40 and… View more

Cardiovascular Kidney Metabolic

Heart Failure
AHA 25 Late-breaking Discussion: Analysis from the SURPASS-CVOT Trial
Author(s): Harriette Van Spall , Stephen Nicholls Added: 6 months ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Prof Stephen Nicholls (Monash University, AU) to present the findings of this AHA late-breaking trial.This pre-specified analysis of the SURPASS-CVOT randomised clinical trial evaluates the comparative effects of once-weekly tirzepatide versus dulaglutide on heart failure outcomes in… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
HFA 2026: UF-CARE — Ultrafiltration in Type 2 Cardiorenal Syndrome
Author(s): Guillaume Baudry Added: 2 weeks ago
HFA Congress 2026 — Dr Guillaume Baudry (University Hospital of Brabois, Nancy, FR) joins us to discuss findings from the UF-CARE trial, evaluating ultrafiltration against enhanced medical therapy in patients with type 2 cardiorenal syndrome.This randomised, open-label study enrolled patients with severe, refractory heart failure and concurrent chronic kidney disease, a population with a high… View more

Cardiovascular Kidney Metabolic

Heart Failure
GLP-1RA in Different HFpEF Phenotypes
Author(s): Aleksandra Bykova , Maria Serova , Maria Chashkina , et al Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Understanding the Role of GLP-1 RAs in the Treatment of HF
Author(s): Giovanni Battista Bonfioli , Matteo Pagnesi , Daniela Tomasoni , et al Added: 9 months ago

Cardiovascular Kidney Metabolic

Heart Failure
GLP-1RAs: Mechanism of Action and Role in HFpEF Management
Author(s): Magdy Abdelhamid , Mostafa M Abdrabou , Emanuel Faris , et al Added: 7 months ago

Heart Failure
Effects of GLP-1 Receptor Agonists in Heart Failure Patients
Author(s): Anastasia Shchendrygina , Amina Rakisheva , Ilya Giverts , et al Added: 1 year ago

Heart Failure
ESC 24: FINE-HEART: Finerenone in HF & CKD
Author(s): Muthiah Vaduganathan Added: 1 year ago
ESC Congress 2024 — Finerenone improved outcomes in two trials in patients with CKD with T2D, and in patients with HFmrEF and HFpEF.Investigator, Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) joins us in London to discuss the findings from the FINE-HEART pooled analysis (Bayer).FINE-HEART is a pre-specified, exploratory pooled analysis combining data from three phase III clinical… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Finerenone: Will It Be a Game-changer?
Author(s): Dinesh Khullar , Anish Kumar Gupta , Kulwant Singh Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic